| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-08-11 | GSK (UK) Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | antisense drugs including inotersen and IONIS-FB-L Rx | licensing - development - commercialisation | Rare diseases - Infectious diseases - Ophtalmological diseases | Licensing agreement | |
| 2017-08-10 | Celgene (USA - NJ) Sutro Biopharma (USA - CA) | multispecific antibodies and antibody drug conjugates (ADCs) | collaboration - option | Cancer - Oncology | Collaboration agreement | |
| 2017-08-10 | Reprocell (Japan) Reprocell Europe (UK) | Reprocell Centre for Predictive Drug Discovery | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-08-10 | Takeda Pharmaceutical (Japan) Shattuck Labs (USA - TX) | checkpoint fusion proteins | research - collaboration | Cancer - Oncology | Research agreement | |
| 2017-08-10 | Alexion Pharmaceuticals (USA - CT) Sema4 (USA - CT) | data sciences, rare disease genomic shields | collaboration | Technology - Services - Rare diseases | Collaboration agreement | |
| 2017-08-10 | Orchard Therapeutics (UK) | president and chief executive officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-08-09 | BioNTech (Germany) Metropolis Healthcare (India) | MammaTyper® | breast cancer | commercialisation | Cancer - Oncology - Diagnostic | Commercialisation agreement |
| 2017-08-08 | Galena Biopharma (USA - OR) | resignation - restructuring | Cancer - Oncology - Hematological diseases | Restructuring | ||
| 2017-08-08 | Selvita (Poland) The Leukemia & Lymphoma Society (USA - NY) | SEL120 | acute myeloid leukemia (AML) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-08-07 | Paion (Germany) R-Pharm (Russia) | remimazolam | sedation, general anaesthesia | development - licensing - manufacture - production - commercialisation |
CNS diseases | Licensing agreement |
| 2017-08-07 | Alligator Bioscience (Sweden) Stanford University (USA - CA) | potential systemic biomarkers | research - collaboration | Cancer - Oncology | Collaboration agreement | |
| 2017-08-07 | Uniqure (The Netherlands) | chief operating officer, chief scientific officer, general manager, members of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-08-03 | Regeneron Pharmaceuticals (USA - NY) Sanofi (France) | fully human therapeutic antibodies | development - commercialisation | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Termination of an agreement | |
| 2017-08-03 | Molecular Templates (USA - TX) Takeda Pharmaceutical (Japan) | oncology drug discovery programs based on engineered toxin bodies (ETB) technology platform | research - licensing | Cancer - Oncology | Research agreement | |
| 2017-08-03 | Cardurion Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan) | cardiovascular diseases | research | Cardiovascular diseases | Research agreement | |
| 2017-08-02 | Biophytis (France) | nomination | Ageing diseases - Muscle disorders - Ophtalmological diseases | Nomination | ||
| 2017-08-01 | Seedsupply (Japan) Takeda Pharmaceutical (Japan) | opening of new premises | Opening of new premises | |||
| 2017-08-01 | Takeda Pharmaceutical (Japan) Isogenica (UK) | monoclonal antibody | licensing | Licensing agreement | ||
| 2017-08-01 | BMS (USA - NY) Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan) | pharmaceutical manufacturing facility in Bothell | plant acquisition | Plant acquisition | ||
| 2017-08-01 | Epizyme (USA - MA) US Oncology Research (USA - TX) | relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with EZH2 mutations | clinical research | Cancer - Oncology - Rare diseases | Clinical research agreement |
